文献速递前列腺癌

炎症性肠病对前列腺癌治疗决策的影响

Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease.
PubMed 文献 · Urology · 2017-02-03

该研究利用美国退伍军人健康管理局2005至2008年确诊的52,311例前列腺癌患者数据,比较合并与不合并炎症性肠病(IBD)男性的治疗差异及IBD发作风险。结果显示,合并IBD者低危前列腺癌更多且更常接受手术,但治疗方式并未预测治疗后一年内的IBD发作。

要点

  • 52,311例前列腺癌患者中,240例(0.5%)在前列腺癌诊断前已患IBD。
  • 合并IBD者较无IBD者更多为白人(P < .001),低危癌症比例更高(P = .02)。
  • 合并IBD者接受手术的比例高于无IBD者(41% vs 28%,P < .001)。

核心结论

  • 合并IBD的前列腺癌患者更可能为低危疾病并接受手术治疗。
  • 前列腺癌治疗方式的选择并未预测治疗后一年内的IBD发作。

研究设计与样本

  • 利用美国退伍军人健康管理局癌症登记和行政数据,识别2005年至2008年确诊的52,311例前列腺癌男性。
  • 通过ICD-9编码、药房和利用数据识别IBD诊断、IBD定向治疗及发作(糖皮质激素升级、住院和手术干预)。
  • 比较合并与不合并IBD男性的特征,并使用多变量回归分析不同治疗类型后的IBD发作。

主要发现

  • 240例(0.5%)在前列腺癌诊断前患有IBD。
  • 与无IBD患者相比,IBD患者更多为白人(P < .001),低危癌症比例更高(P = .02)。
  • 合并IBD者接受手术的比例为41%,无IBD者为28%(P < .001)。
  • 治疗后一年内,18%的IBD患者发生发作。
  • 调整后,治疗后一年内发作的唯一预测因素是治疗前一年内发作(调整比值比12.5;95%CI 5.4-29.2)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the influences of inflammatory bowel disease (IBD), a rare but morbid disease with increasing incidence, on prostate cancer management decisions. We examined whether prostate cancer treatment differed for men with IBD, and whether treatment choice was associated with risk of IBD flare. MATERIALS AND METHODS: Using Veterans Health Administration cancer registry and administrative data, we identified 52,311 men diagnosed with prostate cancer from 2005 to 2008. We used International Classification of Diseases-9 codes and pharmacy and utilization data to identify IBD diagnoses, IBD-directed therapy, and flares (glucocorticoid escalation, hospitalization, and surgical intervention). We compared characteristics across men with and without IBD, and used multivariable regression to examine IBD flares after treatment according to treatment type. RESULTS: Two hundred and forty men (0.5%) had IBD prior to prostate cancer diagnosis. Compared to non-IBD patients, IBD patients were more likely Caucasian (P < .001) with lower-risk cancer (P = .02). Surgery was more common in IBD patients (41% vs 28%, P < .001). In the year following prostate cancer treatment, 18% of IBD patients experienced flares. After adjustment, the only predictor of flare in the year after treatment was flare in the year prior to treatment (adjusted odds ratio, 12.5; 95% confidence interval, 5.4-29.2). CONCLUSION: IBD patients were more likely to have lower-risk disease and be treated with surgery. Choice of prostate cancer treatment did not predict flares in the subsequent year. Better understanding of the intersection of IBD and prostate cancer can help inform treatment decisions for the increasing number of men managing both diseases.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Kirk PS, Govani S, Borza T, et al. Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease. Urology. 2017. PMID: 28163082. doi:10.1016/j.urology.2017.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。